ROCCHETTI MARCELLA

Benzoni, P., Arici, M., Giannetti, F., Cospito, A., Prevostini, R., Volani, C., et al. (2024). Striatin knock out induces a gain of function of INa and impaired Ca2+ handling in mESC‐derived cardiomyocytes. ACTA PHYSIOLOGICA, 240(8 (August 2024)) [10.1111/apha.14160]. Detail

Arici, M., Hsu, S., Ferrandi, M., Barassi, P., Ronchi, C., Torre, E., et al. (2024). Istaroxime follow-on compounds: A new class of selective SERCA2a activators for chronic heart failure treatment. Intervento presentato a: XXIV Congress of the italian society of cardiovascular research, Imola, Italy [10.1016/j.vph.2024.107295]. Detail

Molla, D., Frosio, A., Bertoli, G., Piantoni, C., Arici, M., Bartolucci, C., et al. (2024). In-vitro studies of the NaV1.5 S805L Brugada mutation: The resting cell voltage is a critical element in determining the pathological or physiological phenotype of the current. Intervento presentato a: XXIV congress of the italian society of cardiovascular research, Imola, Italy [10.1016/j.vph.2024.107337]. Detail

Metallo, A., D'Angeli, V., Arici, M., Rocchetti, M. (2024). Intracellular Ca2+ dynamics modulation by istaroxime and its metabolite in pulmonary artery smooth muscle cells. VASCULAR PHARMACOLOGY, 155(June 2024), 20-20 [10.1016/j.vph.2024.107334]. Detail

Arici, M., Hsu, S., Ferrandi, M., Barassi, P., Ronchi, C., Torre, E., et al. (2024). Selective SERCA2a activator as a candidate for chronic heart failure therapy. JOURNAL OF TRANSLATIONAL MEDICINE, 22(1) [10.1186/s12967-024-04874-9]. Detail